ClinicalTrials.gg
Active, not recruitingNCT06046222Updated May 26, 2026

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

A Phase 2 interventional study of NS-229 and Placebo in Eosinophilic Granulomatosis With Polyangiitis and Churg-Strauss Syndrome, sponsored by NS Pharma, Inc.. Active, not recruiting at 34 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by NS Pharma, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.

Read the detailed description

The purpose of this randomized, double-blind study is to investigate the efficacy and safety of NS229 compared with placebo over a 28-week study treatment period in subjects with Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving background corticosteroid therapy with or without Mepolizumab/Benralizumab therapy. During the treatment period corticosteroid dose will be tapered.

The key outcomes in the study focus on evaluation of clinical remission, defined as Birmingham Vasculitis Activity Score (BVAS)=0 with a corticosteroid dose of \<=4 mg/day prednisolone/prednisone.

02

Conditions studied

  • Eosinophilic Granulomatosis With Polyangiitis
  • Churg-Strauss Syndrome

Browse trials for

03

In context

Churg-Strauss Syndrome

61 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.

This study's planned enrollment of 45 is below the median of 66 across 30 interventional studies indexed under Churg-Strauss Syndrome.

Browse Churg-Strauss Syndrome studies →

Lead sponsor

NS Pharma, Inc. is the lead sponsor of 16 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide written prior to participation in the study.
  • Male or female subjects aged ≥18 years at the time the informed consent form is signed.
  • Diagnosis of EGPA: Subjects who have been diagnosed with EGPA based on the history or presence of eosinophilia plus at least a history or presence of 2 of additional features of EGPA.
  • Subjects receive background OGC dose of ≥7.5 mg/day with or without stable treatment with Mepolizumab/Benralizumab.
  • Use of adequate .
  • Other inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of either granulomatosis with polyangiitis or microscopic polyangiitis
  • Imminently life-threatening EGPA at the time of screening.
  • History or presence of any form of cancer within 5 years prior to screening.
  • Serious liver, renal, blood, or psychiatric disease
  • Severe or cardiovascular disease uncontrolled with standard treatment
  • Active systemic infections (including TB, pneumonia, Pneumocystis pneumonia, sepsis, and opportunistic infections)
  • Parasitic infection: Subjects with a known parasitic infestation within 6 months prior to screening.
  • positive status
  • Active hepatitis due to virus or virus
  • Known history or presence of venous thromboembolism/venous thrombotic events (deep vein thrombosis and/or pulmonary embolus)
  • laboratory parameter exclusions:

    1. Estimated of \<30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equations
    2. WBC count \<4 × 109/L
    3. Absolute lymphocyte count \<500 cells/mm3
    4. \<1000 cells/mm3
    5. count \<120,000/mm3
    6. \<8 g/dL (\<80 g/L)
  • Subjects who are pregnant, breastfeeding, or planning to become pregnant during the time of study participation
  • History of clinically significant drug or alcohol abuse within the last 6 months
  • Other exclusion criteria may apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    NS-229

    Self-administer NS-229 in consecutive 28 weeks.

    Drug: NS-229

  • Placebo comparator
    Placebo

    Self-administer matching placebo in consecutive 28 weeks.

    Drug: Placebo

Interventions

  • DrugNS-229

    Experimental

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. The proportion of subjects in remission [OGC 4.0]

    The proportion of subjects in remission (oral glucocorticoid \[OGC\] 4.0) at Week 28 of the study treatment period. Definition of remission (OGC 4.0): BVAS of 0 AND OGC dose of prednisolone/prednisone ≤4 mg/day

    Time frame: From Baseline to week 28

Secondary outcomes

  1. The proportion of subjects in remission [OGC 7.5]

    The proportion of subjects in remission (OGC 7.5) at Week 28 of the study treatment period Definition of remission (OGC 7.5): BVAS of 0 AND OGC dose of prednisolone/prednisone ≤7.5 mg/day

    Time frame: From Baseline to week 28

  2. Time to first relapse of EGPA

    Relapse of EGPA will be defined as active disease since the last visit after remission (OGC 4.0) was achieved, characterized by: 1. Active vasculitis (BVAS of \>0); OR 2. Signs and/or symptoms of active asthma with a corresponding worsening in answers on the 6-item Asthma Control Questionnaire (compared with the most recent previous results); OR 3. Active nasal and/or sinus disease (attributable to EGPA) with a corresponding worsening in at least 1 of the answers on the sinonasal symptom questionnaire (compared with the most recent previous assessment).

    Time frame: Up to Week 28

  3. Time to first worsening of EGPA

    Worsening of EGPA will be defined as worsening of active disease since the last visit, characterized by: 1. Active vasculitis (BVAS \>0) and the score greater than the previous visit; OR 2. Signs and/or symptoms of active asthma with a corresponding worsening in answers on the 6-item Asthma Control Questionnaire (compared to the most recent previous score); OR 3. Active nasal and/or sinus disease (attributable to EGPA) with a corresponding worsening in at least 1 of the answers on the sinonasal symptom questionnaire (compared to the most recent previous assessment).

    Time frame: Up to Week 28

07

Study locations

34 sites
08

References and documents

Individual participant data

Plan to share: No — Submission to the FDA

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Sep 21, 2023
StartActual
Dec 20, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06046222
Lead sponsor
NS Pharma, Inc.
Collaborators
Nippon Shinyaku Co., Ltd.
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Dec 20, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion